Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hangzhou’s Attractions Play Big Part In New Pfizer China Investment

This article was originally published in PharmAsia News

Executive Summary

The Hangzhou Economic Development Area has become a highly attractive spot for global pharmas to establish an expanded presence in China, as its integrated platforms, high quality talent pool and incentives help develop a powerhouse of high-end manufacturing. Pfizer’s $350m decision to join the industrial cluster for a new biotech center follows on from others including MSD, Lilly and Bayer.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel